Early access
Sign in
Not yet taking people in United StatesPhase 1

Effects of Stimulant Medications in PTSD

Key facts

Who runs it
University of Chicago
Where
Chicago, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
40 people, planned
Started
15 Sept 2026
Expected to end
15 Sept 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo
  • Adderall
Record updated
24 June 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 18 - 65 years old
  • BMI 19-30 kg/m2
  • English fluency

Who cannot take part

  • Individuals with chronic (non-PRN) treatment with antipsychotic drug (except PRN quetiapine 25mg PO qHS) or D2 antagonist
  • Individuals with medications with significant PD or PK interactions
  • Individuals with current treatment with a stimulant medication
  • Individuals with current moderate or severe substance use disorder, no past stimulant or cocaine use disorder
  • Individuals with current psychotic or bipolar disorder
  • Individuals with past schizophrenia, schizoaffective disorder, psychotic bipolar disorder, stimulant or cocaine use disorder
  • Individuals with unstable or untreated medical disorder that would increase the risk of serious side effects of study drug (unstable hypertension, tachycardia, cardiac arrhythmia, recent MI or stroke, clinically significant neuropsychiatric or neurological disorder)
  • Individuals with current acute or high risk of suicide or suicide attempt in past 6 months
  • Individuals with court or legally mandated treatment
  • Members of a vulnerable population
  • High blood pressure (>140/90)
  • Women who are pregnant, breastfeeding, or planning to become pregnant

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • University of ChicagoChicago, United StatesContact: Hanna MollaNot yet recruiting

About the trial

What the trial wants to find out

While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of five traumatized persons with PTSD reach remission after cycling through evidence-based and/or FDA-approved medications. This is especially unfortunate given that people with PTSD are often from vulnerable populations, or those whose professions entail personal sacrifice. It is clear that new serotonergic antidepressants and atypical antipsychotics will not be sufficient to fix this gap, and new mechanisms of action need to be tested. In the current proposal, the investigators test the hypothesis that mixed amphetamine salts (brand name Adderall), FDA-approved for treating attention deficit hyperactivity disorder (ADHD), can improve PTSD outcomes.

The 2 groups in the trial

  • placeboPlacebo, for comparison

    dextrose

  • AdderallTreatment being tested

    Adderall (20 mg)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Fit questions
Built from NCT07664631, who can take part
Record updated
24 June 2026